SCHEMBL10074197

SCHEMBL10074197

COC(=O)C(CCC(C)=O)N1Cc2c(N)cccc2C1=O

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 6/20 0.44
RAB9A P51151 6/20 0.44
KMT2A Q03164 5/20 0.38
SMN1; SMN2 Q16637 4/20 0.38
NPSR1 Q6W5P4 2/20 0.38
MEN1 O00255 2/20 0.38
MAPT P10636 3/20 0.38
CYP2C9 P11712 2/20 0.38
CYP2C19 P33261 2/20 0.38
GAA P10253 2/20 0.38
ALDH1A1 P00352 1/20 0.38
CYP1A2 P05177 1/20 0.38
CYP2D6 P10635 1/20 0.38
THRB P10828 3/20 0.36
ALOX15 P16050 2/20 0.35
KDM4E B2RXH2 1/20 0.35
POLB P06746 2/20 0.35
LMNA P02545 3/20 0.35
BRD4 O60885 1/20 0.33
TNF P01375 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7849187 0.91 NPC1 (0.44) NPC1RAB9AKMT2ASMN1; SMN2NPSR1
SCHEMBL7859587 0.91 NPC1 (0.44) NPC1RAB9AKMT2ASMN1; SMN2NPSR1
SCHEMBL18747985 0.89 NPC1 (0.43) NPC1RAB9AKMT2ASMN1; SMN2NPSR1
SCHEMBL7911235 0.89 KDM4E (0.38) NPC1RAB9AKMT2ASMN1; SMN2MEN1
SCHEMBL6368923 0.87 KDM4E (0.37) NPC1RAB9AKMT2ASMN1; SMN2MEN1
SCHEMBL13258695 0.87 THRB (0.38) KMT2AMEN1MAPTGAAALDH1A1
SCHEMBL7857212 0.82 TNF (0.39) NPC1RAB9AKMT2ASMN1; SMN2MEN1
SCHEMBL31047967 0.82 TNF (0.39) NPC1RAB9AKMT2ASMN1; SMN2MEN1
SCHEMBL10192666 0.81 NPC1 (0.43) NPC1RAB9AKMT2ASMN1; SMN2NPSR1
SCHEMBL2254579 0.80 NPC1 (0.47) NPC1RAB9AKMT2ASMN1; SMN2NPSR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9522899-B2 Methods for synthesizing 3-(substituted dihydroisoindolinone-2-yl)-2, 6-dioxopiperidine, and intermediates thereof NANJIAN CAVENDISH BIO-ENGINEERING TECHNOLOGY CO., LTD (CN) 2016-12-20 US disclosed
US-20150284359-A1 Methods for synthesizing 3-(substituted dihydroisoindolinone-2-yl)-2, 6-dioxopiperidine, and intermediates thereof Nanjing Cavendish Bio-Engineering Technology Co., Ltd. (CN) 2015-10-08 US disclosed
US-20150284329-A1 Methods for synthesizing 3-(Substituted Dihydroisoindolinone-2-YI)-2, 6-Dioxopiperidine, and intermediates thereof Nanjing Cavendish Bio-Engineering Technology Co., Ltd. (CN) 2015-10-08 US disclosed
US-9085530-B2 Methods for synthesizing 3-(substituted dihydroisoindolinone-2-yl)-2, 6-dioxopiperidine, and intermediates thereof Nanjing Cavendish Bio-Engineering Technology Co., Ltd. (CN) 2015-07-21 US disclosed
US-20120077982-A1 Methods for Synthesizing 3-(Substituted Dihydroisoindolinone-2-YL)-2, 6-Dioxopiperidine, and Intermediates Thereof Nanjing Cavendish Bio-Engineering Technology Co., Ltd. (CN) 2012-03-29 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150284329-A1 Methods for synthesizing 3-(Substituted Dihydroisoindolinone-2-YI)-2, 6-Dioxopiperidine, and intermediates thereof DHPS, QDPR, FDPS NPC1 2049/4885RAB9A 3061/4885KMT2A 1947/4885
US-20120077982-A1 Methods for Synthesizing 3-(Substituted Dihydroisoindolinone-2-YL)-2, 6-Dioxopiperidine, and Intermediates Thereof DHPS, QDPR, FDPS NPC1 1917/4885RAB9A 3181/4885KMT2A 1995/4885
US-20150284359-A1 Methods for synthesizing 3-(substituted dihydroisoindolinone-2-yl)-2, 6-dioxopiperidine, and intermediates thereof DHPS, QDPR, FDPS NPC1 1917/4885RAB9A 3181/4885KMT2A 1995/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.